Acurx Pharmaceuticals Inc. held its annual meeting on July 17, 2025. During the meeting, stockholders elected Carl V. Sailer and Thomas Harrison as Class I directors. The appointment of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. The issuance of shares of common stock underlying Series F Warrants and Wainwright Warrants was approved. The issuance of shares to Lincoln Park Capital Fund, LLC was also approved. An amendment to increase the number of shares available under the 2021 Equity Incentive Plan was approved.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。